Evidence map›Paper›PMID 28452374›Full record

ArticleScientific reports2017

Prognostic significance of huntingtin interacting protein 1 expression on patients with acute myeloid leukemia.

Jinghan Wang, Mengxia Yu, Qi Guo, Qiuling Ma, Chao Hu, Zhixin Ma, Xiufeng Yin, Xia Li, Yungui Wang, Hanzhang Pan and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Huntingtin-interacting protein 1 in cancer progression: a path less explored.Medical oncology (Northwood, London, England) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Frontiers in cell and developmental biology · 2021
    Article
  10. Article
  11. Article
  12. Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2020
    Article
  13. Article
  14. Cancer: From Wild-Type to Mutant Huntingtin.Journal of Huntington's disease · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Jinghan WangDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Mengxia YuInstitute of Hematology, Zhejiang University, Hangzhou, China.
Qi GuoDepartment of Nephrology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.
Qiuling MaDepartment of Hematology, The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, China.
Chao HuInstitute of Hematology, Zhejiang University, Hangzhou, China.
Zhixin MaInstitute of Hematology, Zhejiang University, Hangzhou, China.
Xiufeng YinInstitute of Hematology, Zhejiang University, Hangzhou, China.
Xia LiInstitute of Hematology, Zhejiang University, Hangzhou, China.
Yungui WangInstitute of Hematology, Zhejiang University, Hangzhou, China.
Hanzhang PanInstitute of Hematology, Zhejiang University, Hangzhou, China.
Dongmei WangInstitute of Hematology, Zhejiang University, Hangzhou, China.
Jiansong HuangInstitute of Hematology, Zhejiang University, Hangzhou, China.
Haitao MengDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Hongyan TongDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Wenbin QianDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Zhejiang University · CNFirst Affiliated Hospital Zhejiang University · CNHenan University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntingtin interacting protein 1 (HIP1) is an endocytic protein which is overexpressed in a variety of human cancers and involved in cancer-causing translocation in leukemia. However, the prognostic impact of HIP1 expression on AML remains unclear. In this study, quantification of HIP1 transcript by real-time quantitative PCR in bone marrow blasts was performed in 270 AML patients. As a result, high HIP1 expression was seen more frequently in older patients, M4/M5 morphology and genes of NPM1 and DNMT3A mutations, and underrepresented in favorable karyotype subgroups and CEBPA double allele mutations in our AML patients. We also found high HIP1 expressers showed lower levels of hemoglobin. In addition, overexpression of HIP1 was associated with an inferior overall survival. The prognostic value of HIP1 expression was validated in patients from an independent TCGA cohort. Notably, up-regulation of miR-16, miR-15a, miR-28 and miR-660 were seen in high HIP1 expressers from the two independent cohorts. In vitro, interfereing of HIP1 expression by siRNA suppressed the proliferation of leukemic cells, and downregulation of these miRNAs were seen in THP-1 and Kasumi cell lines after silencing HIP1 expression. In conclusion, the HIP1 gene expression might serve as a reliable predictor for overall survival in AML patients.

Indexed as

Gene Expression Regulation, LeukemicAdultCell Line, TumorCell ProliferationCohort StudiesDNA-Binding ProteinsFemaleGene Expression ProfilingHumansKaplan-Meier EstimateLeukemia, Myeloid, AcuteMaleMicroRNAsMiddle AgedMultivariate AnalysisNucleophosminDNA-Binding ProteinsHIP1 protein, humanMicroRNAsNPM1 protein, humanNucleophosminRNA, MessengerRNA, Small Interfering

Identifiers

PMID28452374
PMCPMC5408226
OpenAlexW2609224526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.